Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Monique Allman

Physician Assistant Katy, TX Physician Assistant

NPI 1659605723 CMS profile 10973379

21820 Kingsland Blvd, Suite 110, Katy, TX 77450

Open in the dashboard

General payments

$11,167

262 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Monique Allman of Katy, TX is reported in the CMS Open Payments database as having received $11,167 across 262 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,034 38
2024 General $1,968 70
2023 General $5,001 63
2022 General $1,282 58
2021 General $880 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Monique Allman
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Monique Allman were reported at $2,034. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Monique Allman Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $880 $132 $37–$438 $132
2022 $1,282 $155 $48–$522 $149
2023 $5,001 $167 $52–$557 $160
2024 $1,968 $178 $55–$600 $164
2025 $2,034 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Genentech USA, Inc. $3,347 10 payments
  2. AstraZeneca Pharmaceuticals LP $2,491 51 payments
  3. GlaxoSmithKline, LLC. $1,196 72 payments
  4. OptiNose US, Inc. $565 24 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $506 15 payments
  6. Pfizer Inc. $254 10 payments
  7. Genzyme Corporation $254 5 payments
  8. Novartis Pharmaceuticals Corporation $217 12 payments
  9. Pharming Healthcare, Inc. $209 9 payments
  10. Octapharma USA, Inc. $177 2 payments
  11. Other $1,951 52 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,926 255 payments
  2. Consulting Fee $2,375 1 payment
  3. Travel and Lodging $772 3 payments
  4. Education $94 3 payments
Products named General payments · program years 2021–2025
  1. Xolair $3,347 10 payments
  2. TRELEGY ELLIPTA $806 58 payments
  3. Xhance $565 24 payments
  4. CUVITRU $423 12 payments
  5. NUCALA $349 11 payments
  6. FASENRA $334 13 payments
  7. BREZTRI $296 10 payments
  8. AIRSUPRA $217 6 payments
  9. TEZSPIRE $214 6 payments
  10. CIBINQO $212 7 payments
  11. Other $3,020 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

529

Median for Physician Assistant: 241

Drug cost

$42,893

Median for Physician Assistant: $4,110

Branded share of claims

13.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 26 $25,862
Breo Ellipta Fluticasone/Vilanterol Brand 11 $8,248
Azelastine Hcl Generic 95 $2,401
Ipratropium Bromide Generic 40 $1,261
Fluocinolone Acetonide Oil Generic 17 $890
Fluticasone Propionate Generic 70 $888
Montelukast Sodium Generic 69 $825
Levocetirizine Dihydrochloride Generic 24 $621
Albuterol Sulfate Hfa Albuterol Sulfate Brand 21 $561
Mupirocin Generic 17 $403

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XOLAIR
  • Genentech USA, Inc. $136
  • Novartis Pharmaceuticals Corporation $65
$201 — —
CUVITRU
  • Takeda Pharmaceuticals U.S.A., Inc. $186
$186 — —
CUTAQUIG
  • Octapharma USA, Inc. $177
$177 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $145
$145 26 —
AYVAKIT
  • Blueprint Medicines Corporation $135
$135 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

262 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record